Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Next Previous
X
Search
Trial Profile

A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions
  • Sponsors Molecular Insight Pharmaceuticals

    • Most Recent Events

    • 18 Mar 2019 Results of a pooled analysis from NCT00339131; NCT00458952; NCT00874614; NCT00659984 trials presented at the 101st Annual Meeting of the Endocrine Society
    • 01 Nov 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
    • 09 Jun 2009 Planned end date changed from 1 Apr 2012 to 1 May 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top